MedPath

HYUNDAI BIOLAND Co., Ltd.

🇰🇷South Korea
Ownership
Public
Employees
331
Market Cap
-
Website
http://www.skbioland.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 3:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 3
1 (50.0%)

RES-SAFE (Resorption, Safety, and Efficacy of Absorbable Collagen Membrane)

Not Applicable
Not yet recruiting
Conditions
Guided Bone Regeneration
First Posted Date
2024-08-26
Last Posted Date
2024-08-26
Lead Sponsor
Hyundai Bioland Co., Ltd.
Target Recruit Count
50
Registration Number
NCT06570265

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

Phase 3
Completed
Conditions
Chondral or Osteochondral Lesion of Talus
First Posted Date
2020-03-17
Last Posted Date
2022-11-29
Lead Sponsor
Hyundai Bioland Co., Ltd.
Target Recruit Count
102
Registration Number
NCT04310215
Locations
🇰🇷

Kyunghee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of

🇰🇷

Gangnam Severance Hospital, Seoul, Gangnam-gu, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.